Drug Profile
SB 249415
Latest Information Update: 09 Oct 2001
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Monoclonal antibodies
- Mechanism of Action Factor IXa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arterial thrombosis
Most Recent Events
- 09 Oct 2001 No-Development-Reported for Arterial thrombosis in USA (Unknown route)
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 13 Jan 1999 New profile